2030年までの北米乳がん治療薬市場予測 - 地域分析 - 薬物療法別 [標的薬物療法 (アベマシクリブ、アドトラスツズマブ エムタンシン、パルボシクリブ、トラスツズマブ、その他の標的薬物療法)、ホルモン薬物療法 (選択的エストロゲン受容体調節剤、アロマターゼ阻害剤)] 、選択的エストロゲン受容体ダウンレギュレーター)、化学療法、免疫療法/生物学的療法]、乳がんの種類(ホルモン受容体、HER2+、トリプルネガティブ乳がん)、流通チャネル(病院の薬局、ドラッグストアと小売薬局、オンライン薬局) )
個別化医療の使用増加が北米の乳がん治療市場を促進
個別化医療には、個々の患者に合わせた治療計画が含まれますとりわけ、遺伝子構造に基づいて。このアプローチは、各患者のがんの固有の特性を考慮するため、高度に的を絞った効果的な治療を可能にします。ゲノミクスと分子診断の進歩により、個別化医療が乳がん治療における実行可能な選択肢になりました。医療提供者は、患者の腫瘍を分子レベルで分析することで、がんの増殖を促進する特定の遺伝子変異やバイオマーカーを特定できます。この情報は、特定の患者にとって最も効果的である可能性が高い、標的療法や免疫療法などの最も適切な治療オプションを選択するために使用できます。乳がん治療における個別化医療の使用には、患者の転帰を大幅に改善する可能性があります。たとえば、2022 年 2 月、NIH の研究者らは、患者の腫瘍と戦う免疫細胞を使用して転移性乳がん患者を治療する免疫療法の実験的な形態である、個別化乳がん治療アプローチを開発し、個別化医療を前進させました。
医療提供者は、個々の患者に合わせた治療を提供することで、成果が得られる可能性を高め、不必要な副作用のリスクを軽減できます。個別化医療は患者の転帰を改善するだけでなく、経済的な利益ももたらします。効果が期待できる治療法を選択することで、医療提供者は効果のない治療法に関連する医療費を削減し、不必要な出費を回避できます。ゲノミクスと分子診断の進歩に伴い、今後数年間で個別化医療がますます利用しやすくなり、標準治療プロトコルに組み込まれる可能性があります。したがって、個別化医療の利用の増加は、北米の乳がん治療市場に新たな成長傾向をもたらすと予想されます。
北米の乳がん治療薬市場の概要
北米の乳がん治療薬市場は、米国、カナダ、メキシコに分割されています。米国はこの地域で最大の市場シェアを占めています。市場の成長は主にこの地域によるもので、この地域は乳がんの罹患率の上昇や新たな治療法開発のための研究開発投資の増加などの要因により、一貫した成長が見込まれている。さらに、ますます多くの市場参加者が北米諸国での地理的拠点を拡大しています。
医療技術と研究の進歩により、患者の転帰を向上させる画期的な治療法の開発が促進されました。ファイザー、ノバルティス、ロシュ、アストラゼネカ、イーライリリーを含むいくつかの大手製薬会社が米国の乳がん治療市場を独占しています。これらの企業は、新しい医薬品や強化された医薬品を市場に導入するために、研究開発に多額の投資を行っています。政府によって制定された規制や政策も市場に影響を与えます。乳がん治療のための新しい薬や治療法は、食品医薬品局 (FDA) の政府機関によって承認されています。今後数年間で、乳がんの治療市場はさらに拡大すると予想されます。
北米乳がん治療薬市場の収益と2030年までの予測(百万米ドル)
北米乳がん治療薬市場のセグメンテーション
北米乳がん治療薬市場は細分化されています薬物療法、乳がんの種類、流通チャネルに基づいて決定されます。
北米の乳がん治療薬市場は、薬物療法に基づいて、標的薬物療法、ホルモン薬物療法、化学療法、免疫療法/生物学的療法に分割されています。分子標的薬治療セグメントは、2022 年にはより大きなシェアを占めました。分子標的薬治療セグメントは、アベマシクリブ、アドトラスツズマブ エムタンシン、パルボシクリブ、トラスツズマブ、およびその他の標的薬物療法にさらにサブセグメント化されています。さらに、ホルモン薬物療法セグメントは、選択的エストロゲン受容体モジュレーター、アロマターゼ阻害剤、選択的エストロゲン受容体ダウンレギュレーターに分類されます。
乳がんの種類に関して、北米の乳がん治療薬市場はホルモン受容体、HER2+、トリプルネガティブ乳がんに分類されます。 2022 年には、ホルモン受容体セグメントがより大きなシェアを占めました。
北米の乳がん治療薬市場は、流通チャネルごとに、病院薬局、ドラッグストアおよび小売薬局、オンライン薬局に分類されます。 2022 年には、病院薬局セグメントがより大きなシェアを占めました。
北米の乳がん治療薬市場は、国ごとに米国、カナダ、メキシコに分類されます。 2022 年の北米乳がん治療薬市場は米国が独占しました。
イーライリリー社、エーザイ株式会社、ノバルティス AG、アストラゼネカ Plc、ファイザー社、ギリアド サイエンス社、メルク社、ジェネンテック社、テバPharmaceutical Industries Ltd および Amgen Inc は、北米の乳がん治療薬市場で事業を展開する大手企業の一部です。
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Breast Cancer Therapeutics Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market - North America Market Analysis
5.1 North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy
6.1 Overview
6.2 North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type
7.1 Overview
7.2 North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Breast Cancer Therapeutics Market - Regional Analysis
9.1 North America Breast Cancer Therapeutics Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 North America Breast Cancer Therapeutics Market, Breakdown, by Country, Revenue (2022) (US$ Million)
9.1.3 North America Breast Cancer Therapeutics Market, by Country
9.1.3.1 US
9.1.3.1.1 US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 US: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 US: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 US: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 US: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 US: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Canada
9.1.3.2.1 Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Canada: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Canada: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Canada: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Canada: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Canada: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 Mexico
9.1.3.3.1 Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 Mexico: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 Mexico: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 Mexico: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 Mexico: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 Mexico: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Amgen Inc
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. North America Breast Cancer Therapeutics Market Segmentation
Table 2. North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. US Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. US Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. US Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. US Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. US Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 20. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 21. Glossary of Terms, Breast Cancer Therapeutics Market
List of Figures
Figure 1. North America Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. North America Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. North America Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Growth Strategies in Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Genentech Inc
9. Teva Pharmaceutical Industries Ltd
10. Amgen Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America breast cancer therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in North America breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution